About 3% of participants discontinued due to side effects
Methods We developed an in vivo genome-editing approach to introduce a gene encoding the glucagon-like peptide-1 (GLP-1) receptor agonist Exendin-4, modified with a secretion signal peptide
Research Dosages Used in Published Studies Dosages in BPC-157 and TB-500 research vary by animal model, route, and study design, and the figures below describe what specific studies used rather than recommendations for any use
The peptide did not cause them, but they happened to appear during use
Diabetologia 59 , 11211140 (2016)
It also includes any situation where the carton is missing, the label is damaged, or you cannot tell whether the medicine was exposed to normal room conditions, heat, or freezing